Avidity Partners Management LP

Position in GMAB — Genmab A/S

CIK 1791827 DALLAS, TX

Back to GMAB Full portfolio

Position in GMAB

as of Mar 31, 2026 · filed May 28, 2026 Compact

Position Value

$1,341,500

-$1,492,100 QoQ

Shares Held

50,000

-45.7% QoQ

Ownership

0.008%

of shares outstanding

% of Portfolio

0.23%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2025

5 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in GMAB Over Time

Shares Held

Position Value (USD)

Derivatives in GMAB

reported options exposure · as of Mar 31, 2025

CallValue

$8,480,098

CallShares

433,100

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Avidity Partners Management LP holds $473,301,645 across 29 Biotechnology names. GMAB ranks #18 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	DNTH	Dianthus Therapeutics, Inc. /DE/	2,104,184	$176,583,121
2	CGON	CG Oncology, Inc.	1,288,948	$87,236,000
3	IMUX	Immunic, Inc.	6,699,411	$74,363,462
4	ORKA	Oruka Therapeutics, Inc.	760,424	$37,298,797
5	JBIO	Jade Biosciences, Inc.	1,400,708	$19,679,947
6	ELVN	Enliven Therapeutics, Inc.	400,000	$15,680,000
7	CNTX	Context Therapeutics Inc.	4,998,267	$13,095,459
8	PVLA	Palvella Therapeutics, Inc.	70,000	$8,725,500

All Filings in GMAB

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,341,500	50,000	-45.7%	Shares	Sole	2026-05-28
2025-12-31	$2,833,600	92,000	-62.9%	Shares	Sole	2026-02-13
2025-09-30	$7,609,227	248,100	-61.8%	Shares	Sole	2025-11-14
2025-06-30	$13,429,000	650,000	+50.1%	Shares	Sole	2025-08-14
2025-03-31	$8,480,098	433,100	—	Call	Sole	2025-05-15
No filing history on record for this holder in this stock.